Compass pathways stock forecast.

CMPS Stock 12 Months Forecast. Based on 6 Wall Street analysts offering 12 month price targets for COMPASS Pathways in the last 3 months. The average price target is $50.17 with a high forecast of $120.00 and a low forecast of $21.00. The average price target represents a 832.53% change from the last price of $5.38. Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a ... Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. Register for your free account today at data ...Nov 29, 2023 · About CMPS. COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. 16 ส.ค. 2566 ... ... Price” requirement (as defined in the Nasdaq rules). COMPASS intends to use the net proceeds from the proposed financing to fund its pivotal ...

COMPASS Pathways (CMPS) Stock Forecast & Price Prediction. Estimation of the future price movement of COMPASS Pathways stock, based on various factors such as …Nov 9, 2021 · What happened. Compass Pathways ( CMPS 6.61%) saw its shares drop more than 22% on Tuesday. The biotech stock, which focuses on mental health treatment, closed at $43.06 on Monday, opened at $40. ...

COMPASS Pathways PLC (CMPS) stock is down -1.77% while the S&P 500 is higher by 1.89% as of 2:59 PM on Thursday, Apr 27. CMPS has fallen -$0.15 from the previous closing price of $8.17 on volume of 236,713 shares. Over the past year the S&P 500 has fallen -1.22% while CMPS has fallen -21.27%. CMPS lost -$0.01 per share the …

In August 2023 COMPASS Pathways announced a major private placement that initially eased concerns regarding group’s cash runway. Find out why CMPS stock is a Sell.We are Compass Pathways, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. News & events. News releases. SEC filings & annual reports. Our annual review. Stock information. Stock quote & chart. Historical price lookup. Corporate governance.WebMar 2, 2022 · COMP360 Overview (August Company Presentation) Psilocybin is a hallucinogenic chemical found in psychedelic mushrooms. It also is in Phase II clinical trials for the treatment of post-traumatic ... It is one of the best psychedelic stocks to invest in. On December 15, EF Hutton analyst Elemer Piros initiated coverage of COMPASS Pathways plc (NASDAQ:CMPS) with a Buy rating and a $38 price target.

Compare with up to 5 Stocks. On Monday 11/06/2023 the closing price of the COMPASS Pathways PLC (spons. ADRs) share was $6.05 on NAS. Compared to the opening price on Monday 11/06/2023 on NAS of ...Web

COMPASS Pathways has a market cap of $299.3 million, and a 52-week range of $6.74 to $49.52. The stock has a price/book ratio of 1.32, and a price-to-free-cash-flow ratio of -6.9.

Company's cash position stands at $248.0 million with a net loss of $33.4 million for Q3 2023. Get the latest COMPASS Pathways plc (CMPS) stock news and headlines to help you in your trading and ...COMPASS Pathways PLC ADR analyst ratings, historical stock prices, earnings estimates & actuals. CMPS updated stock price target summary.Low. $35.00. Average. $71.83. Current Price. $60.31. Overview. Research & Ratings. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume ...On March 3, 2023 the AMA published the Summary of Panel Actions which included the acceptance of the new CPT III code. The application was titled, “Continuous In-Person Monitoring and Intervention during Psychedelic Medication Therapy.”. CPT III codes are a set of temporary codes assigned to emerging technologies, services and procedures.Nov 13, 2023 · Future criteria checks 0/6. COMPASS Pathways's earnings are forecast to decline at 2.7% per annum while its annual revenue is expected to grow at 82.4% per year. EPS is expected to grow by 6.1% per annum. Return on equity is forecast to be -82.5% in 3 years. 2 พ.ย. 2566 ... Stock FTCH logo. FTCH · Farfetch Will Not Announce Third Quarter 2023 ... price prior to the financing, and will be exercisable at the election ...

Shares of psychedelics-inspired medicine developer COMPASS Pathways (NASDAQ: CMPS) jumped more than 5% on Monday, continuing what has been a multi-day uptrend for CMPS stock.; CMPS stock is now up ...LONDON, May 31, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation, today announced that Co-founder and Chief Innovation Officer Dr. Ekaterina Malievskaia will step down from her executive role …The share price of Square, Inc. (SQ) now. What analysts predict: $71.11. 52-week High/Low: $89.97 / $38.85. 50/200 Day Moving Average: $47.45 / $61.43. This figure corresponds to the Average Price over the previous 50/200 days. For Square stocks, the 50-day moving average is the support level today. For Square stocks, the 200-day …Current price today: 6.450 USD (+1.896%) History Forecast Data Market Q&A Comments Buy CRYPTO Select other stock... Current Price 6.450 USD 7 Days Forecast Get It …On March 3, 2023 the AMA published the Summary of Panel Actions which included the acceptance of the new CPT III code. The application was titled, “Continuous In-Person Monitoring and Intervention during Psychedelic Medication Therapy.”. CPT III codes are a set of temporary codes assigned to emerging technologies, services and procedures.

3 พ.ค. 2564 ... Did you miss out on being an early investor in the Cannabis Boom? Investing in Compass Pathways stock ($CMPS) may be your golden ticket.Financial highlights. Net loss for the three months ended 31 March 2023 was $24.2 million, or $0.57 loss per share (including non-cash share-based compensation expense of $4.1 million), compared with $21.2 million or $0.50 loss per share, during the same period in 2022 (including non-cash-share-based compensation expense of $3.1 million).Web

COMPASS Pathways PLC ADR analyst ratings, historical stock prices, earnings estimates & actuals. CMPS updated stock price target summary. While Compass Pathways' (CMPS 0.84%) stock is near $8, the analysts on Wall Street are figuring, on average, that its shares will explode by 458% to reach around $42.30 within the next 12 months.Compass Pathways PLC (NASDAQ:CMPS) Compass Pathways PLC. 5.94. Delayed Data. As of Nov 29. -0.04 / -0.67%. Today’s Change. 5.01. Today ||| 52-Week Range.Biotechnology firm COMPASS Pathways (CMPS) Wednesday announced a private placement of 16.08M American Depositary Shares and warrants to purchase up to 16.08M ADSs at a price of $7.78...5.01 Today ||| 52-Week Range 11.48 -26.03% Year-to-Date Quote Profile News Charts Forecasts Financials Shareholders Competitors vs. Health Technology News Chart Latest CMPS News | Press Releases... 69.32%. Get the latest Compass Pathways PLC (CMPS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.AnaptysBio presently has a consensus target price of $29.00, suggesting a potential upside of 105.09%. COMPASS Pathways has a consensus target price of $46.83, suggesting a potential upside of 683.17%. Given AnaptysBio's stronger consensus rating and higher probable upside, analysts plainly believe COMPASS Pathways is more …It's a gradual path, however, and the stock hasn't moved much overall since the company last provided a financial update on Aug. 11. But in the month of September, Compass shares slid 11.9% ...8 Wall Street research analysts have issued 1-year target prices for Compass' shares. Their COMP share price targets range from $2.25 to $5.00. On average, they expect the company's stock price to reach $3.39 in the next twelve months. This suggests a possible upside of 47.2% from the stock's current price.

Nov 27, 2023 · The Compass Pathways PLC stock price fell by -6.05% on the last day (Monday, 27th Nov 2023) from $6.45 to $6.06. During the last trading day the stock fluctuated 13.20% from a day low at $5.80 to a day high of $6.56. The price has risen in 6 of the last 10 days and is up by 14.99% over the past 2 weeks. Volume has increased on the last day by ...

Stock analysis for Compass Pathways Plc (CMPS:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Compare with up to 5 Stocks. On Thursday 11/30/2023 the closing price of the COMPASS Pathways PLC (spons. ADRs) share was $6.20 on NAS. Compared to the opening price on Thursday 11/30/2023 on NAS ...Stock Price Forecast. The 9 analysts offering 12-month price forecasts for Compass Inc have a median target of 2.70, with a high estimate of 5.00 and a low estimate of 2.00. The median estimate ...And the biotechnology industry's average price-to-sales multiple is 4.7. Thus, if Compass manages to capture a mere 10% of that per year, it could be bringing in $139 million in revenue. Assuming ...Nikkei 225. 30,696.96. -0.95%. Negative. Source: LSEG - data delayed by at least 15 minutes. Get Compass Pathways PLC (CMPS.OQ) real-time stock quotes, news, price and financial information from ...Web17 ต.ค. 2565 ... Math over Myth is your weekly source for psychedelic stock updates, including Compass Pathways and Revive Therapeutics.17 ต.ค. 2565 ... Math over Myth is your weekly source for psychedelic stock updates, including Compass Pathways and Revive Therapeutics.A live webcast of the call will be available on COMPASS Pathway’s website at: First Quarter 2023 Financial Results. The webcast will also be available on the Investors section of the COMPASS Pathways website. The webcast will be archived for 30 days. The call will also be webcast on the COMPASS Pathways website and archived for 30 days.WebAn in-depth look at the leading psychedelic stocks in the U.S stock market this year. Here’s what you need to know. ... Compass Pathways (NASDAQ:CMPS) $350.9 million Developing one psilocybin ...The Compass Pathways Plc (CMPS) stock price forecast for the next 12 months is generally positive, with an average analyst price target of $20.62, representing a +291.30% increase from the current price of $5.27. The highest analyst price target is $35.17, and the lowest is $6.0744.

Dec 26, 2020 · Despite having an IPO just three months ago, Compass Pathways ( CMPS -3.64%) is already up a staggering 224% from its IPO price of $17. If you invested $10,000 in its first-ever public offering ... Stock Price Forecast. The 5 analysts offering 12-month price forecasts for Compass Pathways PLC have a median target of 38.00, with a high estimate of 120.00 ...Shares of Compass Pathways PLC pointed north out of the gate, as the first trade was 37.6% above the initial public offering price. The said Friday that it's upsized , above the …Instagram:https://instagram. jll quarterly reportetrade uninvested cashvalue quarternvidia stock buy or sell COMPASS Pathways's market cap is currently ―. The company's EPS TTM is $-1.981; its P/E ratio is -2.86; COMPASS Pathways is scheduled to report earnings on March 4, 2024, and the estimated EPS forecast is $-0.34. See an overview of income statement, balance sheet, and cash flow financials. Dec 22. Sep 22. reit investing appstock market widget for website Stock Price Forecast The 11 analysts offering 12-month price forecasts for Doximity Inc have a median target of 25.00, with a high estimate of 31.00 and a low estimate of 21.00.View a financial market summary for CMPS including stock price quote, trading volume, volatility, options volume, statistics, and other important company ... how to buy costco shares COMPASS Pathways plc (COMPASS) operates as a mental health care company. The company engages in the development of a new model of psilocybin therapy, in which its investigational COMP360 psilocybin is administered in conjunction with psychological support. Its initial focus is on treatment-resistant depression (TRD), a subset of major ... Based on the most recent data, CMPS has returned 5% so far this year. Meanwhile, stocks in the Medical group have lost about 16.7% on average. This means that COMPASS Pathways PLC Sponsored ADR is ...06:48 PM ET 11/23/2020. Atai Life Sciences, a company that backs Compass Pathways ( CMPS) and other psychedelic drug developers, said Monday that it had closed a $125 million funding round, the ...